Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Date:8/31/2013

fect of P-gp Inducers & Inhibitors on Dabigatran Exposure
The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are major independent factors in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.

  • For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA.
  • For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of PRADAXA and P-gp inhibitors.

ADVERSE REACTIONS
In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in higher rates of major GI bleeds and any GI bleeds compared to warfarin. In patients >75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions. These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer). Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated
In the pivotal trial, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA (0.7 per 100 patient-years for 150 mg dose) than in those who received warfarin (0.6).

Click

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
(Date:12/22/2014)... 22, 2014 TWi Biotechnology, Inc., today ... for AC-201, TWi Biotechnology,s lead drug candidate, from ... China for patent application numbered 201180018154.8.  ... salts, active metabolite for treatment of type II ... treatment using AC-201 for type II diabetes, and ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... 29 InteKrin Therapeutics presented 6 month Phase 2b clinical ... Selective PPAR-gamma Modulator (SPPARM), from Actos® (pioglitazone), yesterday at the American ... , , ... a novel, non-TZD, selective oral PPAR-gamma modulator (SPPARM) designed to improve ...
... CARLSBAD, Calif. , June 29 Isis ... from seven programs in Isis, broad metabolic disease franchise were ... in Orlando .  These presentations included two oral talks ... in patients with type 2 diabetes and Isis, Phase 1 ...
Cached Medicine Technology:InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone 2InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone 3Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 2Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 3Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 4Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 5Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 6Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 7Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 8
(Date:12/22/2014)... 22, 2014 Luxury Linen purveyor Peacock ... of Dallas to provide logistics and support for one ... Alley has a long history of giving back to the ... of this year's Toy Drive were Whataburger® and 99.5 The ... than the holidays. Providing gifts to children who would otherwise ...
(Date:12/22/2014)... NAPW honors Cheryl A. ... Year. She is recognized with this prestigious distinction for ... organization of professional women in the country, spanning virtually ... Women is a vibrant networking community with over 600,000 ... is passionate and committed to best practices that support ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 Recently, BambooFlooringChina.com, ... durable strand woven bamboo flooring collection , and launched ... 25%. The promotion is valid until Jan. 30, 2015. ... woven bamboo is the hardest bamboo flooring available today; ... resembling that of traditional teak hardwoods. Strand woven bamboo ...
(Date:12/21/2014)... Khanna Vision Institute is pleased to announce ... Helicopters holiday event for underprivileged kids. The highlight was ... by an aspen helicopter pilot. In the cover of ... was visible.(please see accompanying video). Helicopter pilots require great ... many pilots with Pi in eye vision correction. ...
Breaking Medicine News(10 mins):Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
... for many with low risk disease, researchers find , ... prostate cancer that has a low risk of progression, ... a suitable treatment option, according to a large-scale study ... to treat localized prostate cancer is controversial because, especially ...
... ... Ridgway, MD is now performing a new procedure at Baptist Medical Center in Jackson, ... is referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, 2010 -- Baptist ...
... families need extra support, study says , FRIDAY, June ... are at increased risk for falling behind in reading ... the American Speech-Language-Hearing Association. , Parents should provide these ... ASHA, which offers the following tips: , Talk ...
... 18 June 2010: There is significant disparity between ,richer, ... to biological treatments for rheumatoid arthritis (RA), according to ... today at EULAR 2010, the Annual Congress of the ... from a separate study show that RA patients report ...
... ... environment, many Adult Learners contact a “For Profit” Online University or ... about returning to school to earn their online degree. What most ... certificates, licenses earned and college level exams successfully completed can all ...
... cost increased, consumption dropped, study found , FRIDAY, June ... soft drinks may reduce consumption and help lower levels ... new study suggests. , Researchers examined what happened during ... Women,s Hospital in Boston increased the price of regular ...
Cached Medicine News:Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2Health News:Country economy is a stronger predictor of therapy initiation 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 3Health News:People May Skip Soft Drinks Rather Than Pay More 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: